ROCKVILLE, Md. – For decades, the field of pharmacogenomics—the study of how an individual’s genetic makeup influences their response to drugs—has been defined by a relatively narrow lens: the single gene-drug pair. It was a world of "one variant, one reaction," where clinicians looked for specific mutations to determine if a patient could safely metabolize a standard dose of a blood thinner or an antidepressant.
However, a paradigm shift is underway. On October 23, 2026, the American Society of Human Genetics (ASHG) announced a pivotal, trainee-led session aimed at dismantling these traditional boundaries. By integrating multiomic data, functional genomics, and real-world electronic health records (EHRs), researchers are moving toward a more holistic understanding of human biology, promising to transform how we predict, prescribe, and personalize medicine.
The New Frontier: Moving Beyond the Single Gene-Drug Paradigm
Historically, pharmacogenomic research has focused on variants with high clinical impact—the "low-hanging fruit" of genomic medicine. While these discoveries have saved countless lives by preventing adverse drug reactions, they often provide only a partial picture.
"We are moving past the era where we look at a single gene in isolation," said Evelyn Mantegani, media contact for the ASHG. "The complexity of drug response is rarely dictated by one piece of the puzzle. By incorporating multiomic data—looking at the proteome, the transcriptome, and the epigenome—we can finally see the systemic interactions that determine why two people with similar genetic profiles might have vastly different clinical outcomes."
The Multiomic Revolution
The upcoming session will highlight how researchers are now using "omics profiling" of cellular models under drug perturbation. This allows scientists to observe how a drug affects the entire biological landscape of a cell in real-time. By measuring these changes, researchers can identify subtle genetic interactions that were previously invisible, providing a much more granular view of how medications work—or fail to work—in different individuals.
Chronology of a Paradigm Shift: From Discovery to Clinical Integration
To understand where pharmacogenomics is headed, one must look at how the field has evolved over the last twenty years:
- 2000s – The Era of Candidate Genes: Initial research focused on identifying specific variants in drug-metabolizing enzymes, such as the CYP450 family. Success stories, like the testing of TPMT variants for thiopurine sensitivity, set the gold standard.
- 2010s – The GWAS Boom: Genome-Wide Association Studies (GWAS) allowed researchers to scan the entire genome for associations between genetic variants and drug responses. While productive, this approach often struggled with "missing heritability," where the identified variants didn’t fully explain the observed differences in patient outcomes.
- 2020s – The Multiomic and Integrative Era: Today, the focus has shifted toward integrating diverse data streams. The current movement involves combining functional assays—where genetic variations are tested in lab-grown "organoids" or cell lines—with massive data sets from biobanks and EHRs to create predictive models that account for environmental, social, and biological variables.
Supporting Data: Why Breadth Matters More Than Depth
One of the most pressing challenges in modern pharmacogenomics is the issue of "transferability." Much of the foundational genomic data currently available was derived from populations of European ancestry. This has created a "genomic divide," where findings that work for one group fail to translate to others.
Addressing the Diversity Gap
The ASHG-led session emphasizes that future research must prioritize historically understudied populations. When pharmacogenomic results are not tested across diverse groups, the clinical utility of those findings is limited, potentially exacerbating health disparities.
Speakers are expected to present new data showing that:
- Functional Genomics: Assays designed to measure drug response in diverse cell lines can identify actionable variants that are unique to specific ancestries.
- Environmental Interactions: Social and environmental factors—often captured in EHRs—can act as "modifiers" that change how a drug is processed. A patient’s diet, exposure to pollutants, or socioeconomic stress levels are now being factored into these complex models.
- Biobank Utility: While large biobanks provide the necessary scale to detect rare variants, they are often plagued by issues of data quality and phenotype definition. The session will explore how to "clean" this data to ensure that findings are both robust and clinically relevant.
Official Perspectives: The Role of the Next Generation
A defining feature of this initiative is its reliance on trainee-led research. By centering emerging scientists, the ASHG is fostering a culture of innovation that is less tethered to the rigid dogmas of the past.
"The next generation of scientists is not just looking at the genome; they are looking at the patient in their entirety," said a spokesperson for the ASHG. "They are asking, ‘How does this person’s life, their environment, and their multiomic profile interact with this specific drug?’ It is a more inclusive, more comprehensive, and ultimately more humane way to approach medicine."
The Society’s leadership emphasizes that the goal is not just academic publication, but actionable clinical outcomes. As the field moves toward large-scale, automated EHR integration, the potential to implement "precision prescribing" at the point of care becomes a reality.
Implications: The Future of Clinical Practice
The transition from a "one-size-fits-all" model to a high-fidelity, personalized approach has profound implications for global healthcare systems.
1. Reducing Adverse Drug Events (ADEs)
ADEs remain a leading cause of hospitalization and morbidity. By utilizing more comprehensive models that account for multiomic variation, healthcare providers can proactively identify patients at risk for adverse reactions before the first dose is ever prescribed.
2. Enhancing Drug Efficacy
For chronic conditions like cancer, hypertension, and mental health disorders, finding the right drug is often a process of trial and error. Multiomic profiling offers a shortcut, enabling physicians to select the most effective treatment based on the biological reality of the patient, rather than statistical averages.
3. Addressing Health Equity
By consciously shifting the focus toward diverse populations, the scientific community is taking a significant step toward closing the gap in health outcomes. The inclusion of diverse genetic data ensures that the benefits of the genomic revolution are equitably distributed, rather than being concentrated among populations already well-represented in existing databases.
Conclusion: A More Informative Future
The movement within pharmacogenomics is clear: the field is maturing. It is moving out of the laboratory’s isolation and into the messy, complex, and vital world of human health. By embracing the complexity of multiomics, the importance of diversity, and the vast potential of real-world data, researchers are laying the groundwork for a future where medicine is truly, and effectively, personalized.
As the American Society of Human Genetics continues to lead this dialogue, the message to the clinical and research community is clear: to understand the drug, one must first understand the whole person.
About the American Society of Human Genetics (ASHG)
The American Society of Human Genetics (ASHG) is the leading global organization advancing the science of human genetics and genomics. Representing nearly 8,000 researchers, clinicians, genetic counselors, educators, and other professionals, ASHG drives progress in understanding the human genome and its role in health and disease. The Society fosters innovation and collaboration through its flagship events and publications—including the ASHG Annual Meeting and its peer-reviewed journals The American Journal of Human Genetics and Human Genetics and Genomics Advances. ASHG also champions science advocacy, supports the next generation of genetics professionals, and promotes responsible policies and public engagement in genetics. Learn more at www.ashg.org.
About the Author
